A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

NCT06756490 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate or Severe Submental Fullness

Interventions

DRUG: HY-2003 (10 mg/ml), BELKYRA and placebo
DRUG: HY-2003 (5 mg/ml) and placebo
DRUG: HY-2003 (5 mg/ml) and placebo

Sponsor

Sichuan Huiyu Pharmaceutical Co., Ltd

Collaborators

[object Object]
[object Object]